Form 8-K · Current report
Cencora 8-K, filed Nov 4, 2026
- Filed
- CIK
- 0001140859
- Accession no.
- 0001140859-26-000038
Summary
Cencora reported fiscal 2026 fourth-quarter revenue of $88.4 billion, up 5.5 percent, with adjusted diluted EPS of $4.66, and full-year revenue of $337.4 billion, up 5.0 percent. The company guided fiscal 2027 adjusted diluted EPS to $19.40–$19.75 (8–10 percent growth), introduced new reportable segments with long-term growth targets, and raised its quarterly dividend by 10 percent.
Key points
- Fourth-quarter GAAP diluted EPS was $2.71 versus $(1.75) in the prior-year quarter, which included a $723.9 million PharmaLex goodwill impairment charge.
- Fiscal 2026 GAAP diluted EPS was $17.95 and adjusted diluted EPS was $17.97.
- CEO Robert P. Mauch credited expansion of the MSO platform through the February 2026 OneOncology acquisition for record results.
- Higher GLP-1 sales lifted revenue but carried lower gross profit margins.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 7.01Regulation FD Disclosure
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02. Results of Operations and Financial Condition. Earnings Release for the Fiscal Quarter and Year Ended September 30, 2026 On November 4, 2026, Cencora, Inc. (the “Company”) issued a news release announcing the Company’s earnings for the fiscal quarter and year ended September 30, 2026. A copy of the news release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information in this Current Report, including the exhibit attached hereto as Exhibit 99.1 and the information under Item 7.01 below, is being furnished to the Securities and Exchange Commission and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.